ELMMB logo
Facebook logo Twitter logo
Menu
Home

Recently Updated Documents

Information on this website has been provided by the East Lancashire Medicines Management Board which oversees Medicines Management issues across the East Lancashire Health Economy (population 522,000), which consists of;

Blackburn with Darwen CCG 
East Lancashire CCG
East Lancashire Hospitals NHS Trust  

The Medicines Management Board (MMB) consists of physicians and representatives of other key decision-makers in the use of medicines in primary and secondary care. The remit of this board is to review selected pharmaceutical products to assess their clinical value, safety and suitability for use in the East Lancashire Health Economy, and to guide all prescribers in primary and secondary care in using them appropriately.  

 Overarching Policy for the Managed Introduction of New Drugs (Priority setting of Medicines)
Appendix 1a East Lancashire Medicines Management Board Terms of Reference  
Appendix 4   Submitting a request to the ELMMB to Review a Medicine
Appendix 8   ELMMB Decision Map

Clinical Commissioning Groups (CCGs) in East Lancashire aim to commission the provision of high quality clinical care for the population equitably and consistently, based solely on clinical need and within the resources available. The best way to achieve this is by commissioning clear pathways of care which span the interfaces between primary and secondary care (and tertiary when required) and are supported by shared clinical protocols, policies and arrangements for audit and outcome evaluation. To achieve this aim and ensure that the commissioning of medicines is clinically led, joint decision making with the local main NHS provider (ELHT) takes place to ensure consistency of decisions between primary and secondary care, which are ‘owned’ by clinicians in both sectors.

Within East Lancashire the Medicines Management Board (MMB) is the decision making committee, responsible for critically reviewing the evidence base and cost effectiveness of all medicines, whilst being able to effectively relate the priority and costs of these medicines to that of the overall CCG and national NHS priorities.  

In accordance with Secretary of State Directions an overarching policy which outlines the framework and defines the decision making process within the Medicines Management Board has been produced and can be found below.

Request for a New Medicine: Overview

CCGs are increasingly being requested to fund new and innovative treatments by clinicians and patients. in an era of finite resources It can not be expected that new medicines are introduced in an ad hoc basis through the mechanism of individual case funding. To do so would risk inequity, since the treatment would not be offered openly and equally to all with equal clinical need. It would also risk diverting resources in such a way that would destabilise other areas of healthcare identified as priorities. Therefore, decisions on the introduction of new medicines will take place on a population level,  within the established planning frameworks of the NHS after consideration by the appropriate committees.

Any NHS healthcare professional working within the East Lancashire health economy can request that the MMB considers an application to assess a new medicine, and prioritise it against other competing requests.

Where a clinician is considering requesting an intervention for a patient that is not already commissioned, but this patient represents the first of many, this will be considered only as a Service Development. As such, the clinican should request the intervention for all patients, The process for applying for a medicine to be reviewed as a service development by the MMB can be found below with the application form for a 'New Product, or Change of Regimen' and guidance relating to the governance arrangements of documents submitted to East Lancashire Medicines Management Board.

Individual  Funding Requests and Exceptional Cases

Individual Funding Requests:                                                                                                                                                            Where no policy exists for a very rare condition or experimental medicine

The CCG have set up an Individual Cases process to consider the circumstances of individuals, for whom a referral outside existing pathways may be appropriate. This usually relates to patients with rare conditions, or for more experimental treatments where there is very sparse evidence.  in such instances Clinicians should obtain an individual funding request form- see below. 

Exceptional Cases:                                                                                                                                                                                        Where a policy not to fund a medicine is already in place

If an individual falls outside the range of services and treatments that the CCG has agreed to commission then an Exceptional Funding Request can be made by a clinician, on behalf of a patient,  to fund healthcare. The responsibility for demonstrating exceptionality lies with the requesting clinician and based on the information provided the CCG must decide whether or not to support this view and agree to fund the request.

Should you wish to apply for exceptional funding please use the form below.

twitter-icon.png

Twitter

Register

Keep up to date with Medicines Management Issues.

Receive monthly updates by email about new updates to the site

 

Register Here